Search results
Showing 796 to 810 of 864 results for score
Evidence-based recommendations on the bisphosphonates alendronic acid, ibandronic acid, risedronate sodium and zoledronic acid for treating osteoporosis.
Digital platforms to support cardiac rehabilitation: early value assessment (HTG764)
Early value assessment (EVA) on digital platforms to support cardiac rehabilitation.
New sepsis guideline targets faster, tailored treatments to benefit patients
Patients aged 16 or over with suspected sepsis will receive more tailored treatment under updated NICE guidance published today.
Methods for the development of NICE public health guidance (third edition) (PMG4)
This manual describes the methods used by the Centre for Public Health Excellence (CPHE) in NICE to develop and update public health guidance
Digitally enabled therapies for adults with depression: early value assessment (HTG675)
Early value assessment (EVA) guidance on digitally enabled therapies for adults with depression.
Evidence-based recommendations on the Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain.
Evidence-based recommendations on niraparib (Zejula) for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults.
Cabozantinib for previously treated advanced renal cell carcinoma (TA463)
Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advance renal cell carcinoma in adults.
Evidence-based recommendations on crizotinib (Xalkori) for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults.
Evidence-based recommendations on ceritinib (Zykadia) for treating advanced anaplastic lymphoma kinase positive non-small-cell lung cancer in adults who have had crizotinib.
Evidence-based recommendations on testing for epidermal growth factor receptor tyrosine kinase (EGFR–TK) mutations in untreated, locally advanced or metastatic non-small-cell-lung cancer.
This indicator covers those patients aged between 25 and 84 years, with a new diagnosis of hypertension or type 2 diabetes recorded in the preceding 12 months (excluding those with pre-existing cardiovascular disease, chronic kidney disease, familial hypercholesterolaemia or type 1 diabetes), who have a recorded cardiovascular risk assessment score of 10% or more in the preceding 12 months: the percentage who are currently treated with a lipid lowering therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Evidence-based recommendations on obecabtagene autoleucel (obe-cel; Aucatzyl) for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in adults.
NICE has developed a medtech innovation briefing (MIB) on Aptiva for painful diabetic neuropathy .
Evidence-based recommendations on viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems).